The U.S. Food and Drug Administration (FDA) has granted fast track designation to Alessa Therapeutics for its lead product ...

Enolen is currently being studied in a Phase 1 trial evaluating its safety, tolerability and preliminary efficacy for localized sustained delivery of enzalutamide into the prostate. Alessa expects to ...

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...

Cam Gallagher, President and CEO, and Pamela Munster, MD, Founder and Chief Scientific Advisor, will present a company ...

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized ...

Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post ...

New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

An Alabama Senate committee unanimously approved a bill Wednesday morning that would require health insurance companies to ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...